Aiming for a massive goal like 'a billion dollars' is paralyzing. The key is to invert the problem and focus on immediate survival. By identifying and avoiding existential threats, a company lives long enough for knowledge and success to compound, eventually reaching the goal.
In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.
Wearables and remote devices generate a massive volume of data that physicians cannot realistically analyze. For continuous care to be effective, it requires powerful AI-driven analytics systems to sift through the noise, identify trends, and provide actionable insights for clinicians.
Healthcare systems were designed for acute, symptomatic diseases. This "wait for the patient" model is ineffective for chronic conditions like hypertension, which are often asymptomatic for years. The future requires a shift from sporadic visits to continuous, proactive, tech-enabled care.
Health plans have short-term incentives misaligned with long-term chronic care savings. Employers, who bear the costs longest, are the true economic buyers. By acquiring a broker and sharing in cost savings, a startup can align incentives and scale effectively.
Health tech can't burn cash indefinitely like other tech sectors due to long timelines and complexity. Founders must design their company to achieve profitability at multiple stages, creating self-sustaining platforms before pursuing the next level of growth and investment.
For health tech companies, Brazil is a powerful proving ground. Its large, self-contained private market operates very similarly to the U.S. system. Validating a product and business model in Brazil provides a strong signal and a potential pathway for successful expansion.